Teva- Pharmaceutical Industries Ltd ADR(TEVA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 61.96 | EPS (ttm) | 0.59 | Insider Own | 0.07% | Shs Outstand | 1.17B | Perf Week | 1.82% |
| Market Cap | 42.94B | Forward P/E | 12.02 | EPS next Y | 54.23% | Insider Trans | -48.11% | Shs Float | 1.16B | Perf Month | 1.96% |
| Enterprise Value | 56.16B | PEG | 2.16 | EPS next Q | 0.7 | Inst Own | 63.54% | Short Float | 3.06% | Perf Quarter | 6.97% |
| Income | 0.70B | P/S | 2.46 | EPS this Y | -32.18% | Inst Trans | 2.01% | Short Ratio | 6.46 | Perf Half Y | 16.91% |
| Sales | 17.45B | P/B | 5.54 | EPS next 5Y | 5.56% | ROA | 1.75% | Short Interest | 35.67M | Perf YTD | 18.07% |
| Book/sh | 6.65 | P/C | 11.75 | EPS past 3/5Y | - | ROE | 9.6% | 52W High | -3.96% ($38.37) | Perf Year | 87.25% |
| Cash/sh | 3.14 | P/FCF | 29.24 | Sales past 3/5Y | 5.53% 0.8% | ROIC | 3.48% | 52W Low | 102.36% ($18.21) | Perf 3Y | 283.06% |
| Dividend Est. | - | EV/EBITDA | 13.14 | EPS Y/Y TTM | 534.09% | Gross Margin | 52.53% | Volatility(W/M) | 3.69% 2.74% | Perf 5Y | 298.38% |
| Dividend TTM | - | EV/Sales | 3.22 | Sales Y/Y TTM | 4.33% | Oper. Margin | 18.79% | ATR (14) | 1.09 | Perf 10Y | -26.61% |
| Dividend Ex-Date | 2017/11/27 | Quick Ratio | 0.67 | EPS Q/Q | -302.7% | Profit Margin | 4.01% | RSI (14) | 54.82 | Recom | 1.43 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.88 | Sales Q/Q | -1.79% | SMA20 | -0.14% ($36.9) | Beta | 0.9 | Target Price | $43.56 |
| Payout | - | Debt/Eq | 2.18 | Earnings | 2026/7/29 | SMA50 | 6.03% ($34.75) | Rel Volume | 0.69 | Prev Close | $36.76 |
| Employees | 33346 | LT Debt/Eq | 1.6 | EPS/Sales Surpr. | -61.39% 3.02% | SMA200 | 12.7% ($32.7) | Avg Volume(3M) | 5.52M | Price | $36.85 |
| IPO | 1982/2/16 | Option/Short | Yes/Yes | Trades | 21643 | Volume | 3,830,058 | Change | 0.24% |
Company
TEVA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 This US-listed ADR represents a multinational pharmaceutical company that is a leading player in the global generic drugs sector and also operates select innovative and biosimilar drugs. Founded in 1901 in Israel and headquartered in Tel Aviv, the company runs a global generic drug supply chain along with a new drug pipeline spanning various therapeutic areas.
Over the past 1 year, on the higher side
4% below its 1-year high.
TEVA has weak earning power
18.79% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -32.2% this year.
Tap to view numbers
The price looks about right
Trading at 62.0 times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +283.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 63.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
EIS 0.09%
ISRA 0.07%
WCME 0.04%
WCMI 0.03%
PPH 0.03%It ranks #2 in the industry
Based on market cap of $43B.
TEVA $43B PER 62.0
TAK $58B PER -
HLN $41B PER 19.0
ZTS $30B PER 12.1
FAQ
What kind of company is TEVA?
TEVA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of TEVA?
The market cap of TEVA is approximately $42.9B, ranking 366 within its sector.
What is the P/E ratio of TEVA?
TEVA has a P/E ratio of approximately 62.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for TEVA?
TEVA has recorded a 52-week high of $38.37 and a low of $18.21.
